NuVasive's stock rose 5.8 percent Jan. 6 after publication of its study regarding single-position spine surgery in The Spine Journal, according to Seeking Alpha.
Three details:
1. The study found significant advantages of NuVasive's X360 approach to lateral single-position spine surgery over traditional open fusion. Benefits included fewer complications, less blood loss and reduced length of stay.
2. Researchers evaluated 390 patients who had anterior lumbar interbody fusion and/or lateral lumbar interbody fusion surgery with bilateral percutaneous pedicle screw fixation between L2-S1
3. Single-position lateral surgery reduced operating time by more than three hours and decreased average hospital stay by two days, according to the study.